Market Cap : 125.12 B | Enterprise Value : 137.24 B | PE Ratio : 25.25 | PB Ratio : 2.39 |
---|
NYSE:MDT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:MDT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Good Sign:
Piotroski F-Score is 8, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Medtronic has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Medtronic's Piotroski F-Score or its related term are showing as below:
During the past 13 years, the highest Piotroski F-Score of Medtronic was 8. The lowest was 1. And the median was 6.
The historical data trend for Medtronic's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medtronic's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Medtronic's Piotroski F-Score falls into.
How is the Piotroski F-Score calculated?
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Apr22) TTM: | Last Year (Apr21) TTM: |
Net Income was 763 + 1311 + 1480 + 1485 = $5,039 Mil. Cash Flow from Operations was 1292 + 1769 + 2228 + 2057 = $7,346 Mil. Revenue was 7987 + 7847 + 7763 + 8089 = $31,686 Mil. Gross Profit was 5389 + 5350 + 5304 + 5498 = $21,541 Mil. Average Total Assets from the begining of this year (Apr21) to the end of this year (Apr22) was (93083 + 91802 + 91756 + 91804 + 90981) / 5 = $91885.2 Mil. Total Assets at the begining of this year (Apr21) was $93,083 Mil. Long-Term Debt & Capital Lease Obligation was $20,372 Mil. Total Current Assets was $23,059 Mil. Total Current Liabilities was $12,394 Mil. |
Net Income was 487 + 489 + 1270 + 1360 = $3,606 Mil. Revenue was 6507 + 7647 + 7775 + 8188 = $30,117 Mil. Gross Profit was 4002 + 4942 + 5154 + 5535 = $19,633 Mil. Average Total Assets from the begining of last year (Apr20) to the end of last year (Apr21) was (90689 + 93906 + 95886 + 97270 + 93083) / 5 = $94166.8 Mil. Total Assets at the begining of last year (Apr20) was $90,689 Mil. Long-Term Debt & Capital Lease Obligation was $26,378 Mil. Total Current Assets was $22,548 Mil. Total Current Liabilities was $8,509 Mil. |
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Medtronic's current Net Income (TTM) was 5,039.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Medtronic's current Cash Flow from Operations (TTM) was 7,346.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Score 1 if it's higher, 0 if it's lower.
ROA (This Year) | = | Net Income | / | Total Assets (Apr21) |
= | 5039 | / | 93083 | |
= | 0.05413448 |
ROA (Last Year) | = | Net Income | / | Total Assets (Apr20) |
= | 3606 | / | 90689 | |
= | 0.03976226 |
Medtronic's return on assets of this year was 0.05413448. Medtronic's return on assets of last year was 0.03976226.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Score 1 if CFROA > ROA, 0 if CFROA <= ROA.
Medtronic's current Net Income (TTM) was 5,039. Medtronic's current Cash Flow from Operations (TTM) was 7,346.
==> 7,346 > 5,039 ==> CFROA > ROA ==> Score 1.
Funding
Question 5. Change in Gearing or Leverage
Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.
Score 0 if this year's gearing is higher, 1 otherwise.
Gearing (This Year: Apr22) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Apr21 to Apr22 |
= | 20372 | / | 91885.2 | |
= | 0.22171144 |
Gearing (Last Year: Apr21) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Apr20 to Apr21 |
= | 26378 | / | 94166.8 | |
= | 0.28011996 |
Medtronic's gearing of this year was 0.22171144. Medtronic's gearing of last year was 0.28011996.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Current Ratio (This Year: Apr22) | = | Total Current Assets | / | Total Current Liabilities |
= | 23059 | / | 12394 | |
= | 1.86049701 |
Current Ratio (Last Year: Apr21) | = | Total Current Assets | / | Total Current Liabilities |
= | 22548 | / | 8509 | |
= | 2.64990011 |
Medtronic's current ratio of this year was 1.86049701. Medtronic's current ratio of last year was 2.64990011.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Medtronic's number of shares in issue this year was 1343.9. Medtronic's number of shares in issue last year was 1357.9.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Gross Margin (This Year: TTM) | = | Gross Profit | / | Revenue |
= | 21541 | / | 31686 | |
= | 0.67982705 |
Gross Margin (Last Year: TTM) | = | Gross Profit | / | Revenue |
= | 19633 | / | 30117 | |
= | 0.65189096 |
Medtronic's gross margin of this year was 0.67982705. Medtronic's gross margin of last year was 0.65189096.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Asset Turnover (This Year) | = | Revenue | / | Total Assets at the Beginning of This Year (Apr21) |
= | 31686 | / | 93083 | |
= | 0.34040587 |
Asset Turnover (Last Year) | = | Revenue | / | Total Assets at the Beginning of Last Year (Apr20) |
= | 30117 | / | 90689 | |
= | 0.33209099 |
Medtronic's asset turnover of this year was 0.34040587. Medtronic's asset turnover of last year was 0.33209099.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score | = | Que. 1 | + | Que. 2 | + | Que. 3 | + | Que. 4 | + | Que. 5 | + | Que. 6 | + | Que. 7 | + | Que. 8 | + | Que. 9 |
= | 1 | + | 1 | + | 1 | + | 1 | + | 1 | + | 0 | + | 1 | + | 1 | + | 1 | |
= | 8 |
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Medtronic has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Thank you for viewing the detailed overview of Medtronic's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Fong Ivan K | officer: EVP GENERAL COUNSEL & SECR | 3M CENTER ST. PAUL MN 55144-1000 |
Kirk Jennifer M | officer: Chief Accounting Officer | 5 GREENWAY PLAZA SUITE 110 HOUSTON TX 77046 |
Lofton Kevin E | director | GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY CA 94404 |
Wall Brett A. | officer: EVP & Group Pres Restora Thera | 710 MEDTRONIC PARKWAY LC300 MINNEAPOLIS MN 55432 |
Salmon Sean | officer: EVP & Group President Diabetes | MEDTRONIC PLC, 710 MEDTRONIC PARKWAY LC300 MINNEAPOLIS MN 55432 |
Goldsmith Andrea Jo | director | 1220 AUGUSTA DRIVE SUITE 600 HOUSTON TX 77057 |
Liddicoat John R | officer: EVP & President of Americas | MEDTRONIC PLC 710 MEDTRONIC PKWY, MS LC300 MINNEAPOLIS MN 55432 |
White Robert John | officer: EVP & President MITG | MEDTRONIC PLC 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 |
Parkhill Karen L | officer: EVP & Chief Financial Officer | 1717 MAIN STREET, MC 6402 DALLAS TX 75201 |
Reddy Preetha | director | APOLLO HOSPITALS 21 GREAMS LN, OFF GREAMS RD CHENNAI K7 600006 |
Ellis Gary Lee | officer: EVP & Chief Financial Officer | THE TORO COMPANY 8111 LYNDALE AVENUE SOUTH BLOOMINGTON MN 55420 |
Hanson Bryan C | officer: EVP AND PRESIDENT, COVIDIEN | ZIMMER BIOMET HOLDINGS 345 E. MAIN STREET WARSAW IN 46580 |
Hakami Hooman | officer: EVP & Group President Diabetes | 710 MEDTRONIC PKWY MSLC300 MINNEAPOLIS MN 55432 |
Oconnell Christopher J | officer: See Remarks | MEDTRONIC, INC. 710 MEDTRONIC PKWY MINNEAPOLIS MN 55432 |
Lenehan James T | director | C/O MEDTRONIC INC 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 |
Other Sources
By Zacks 2022-03-10
By Fool 2022-03-02
By Zacks 2022-04-01
By Zacks 2022-04-05
By Zacks 2022-03-23
By Zacks 2022-03-24
By Zacks 2022-03-03
By Zacks 2022-03-24
By tipranks.com 2022-02-23
By Zacks 2022-03-01
By Zacks 2022-03-28
By Zacks 2022-04-05
By Fool 2022-03-09
By Zacks 2022-03-02
By Zacks 2022-02-22